Compare RAPT & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
UTStarcom Holdings Corp operates as a telecom infrastructure provider. It develops technology for bandwidth from cloud-based services, mobile, streaming, and other applications. The range of solutions is designed to expand and modernize telecommunications networks through smooth network system integration, lower operating costs, and increased broadband access. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. The company operates in China, India, Japan, Taiwan and other countries.